← brief for 2026-10-15 · Slowing decline

Cardiometabolic Efficacy and Renal Safety of Saroglitazar in Indian Patients with Type 2 Diabetes — a 36-Month Retrospective Observational Study

Article C Peer reviewed Observational

Key takeaways

This study looked at 110 people with type 2 diabetes who took a drug called saroglitazar for three years. It checked how the drug affected their blood sugar, cholesterol, and kidney function. Because it was an observational study, it shows a link but not proof of cause. The results help doctors understand the long-term safety of this drug for people with kidney issues.

Who did this work

Gaurav Chhaya · Kunal S Jhaveri · Haresh Patel (Apollo Hospitals) · Gauri Aware (Zydus Lifesciences Limited (India))

Source

Article · OpenAlex, CKD works · 2026-10-14
https://doi.org/10.5603/cd.113967